Reports suggest that the UK government has agreed to pay higher prices for prescription medicines, with the suggestion that this is a response to a demand from the US Trump administration. Meanwhile, some companies in Australia have paused the progression of PBS listings in response to MFN uncertainty. …
UK moves to pricing changes as Australian-based companies baulk at listings
June 5, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Patients and clinicians defend MS treatment choice during review stakeholder meeting
November 5, 2026 - - Latest News -
Vaccines dominate public health spending but prevention investment slips
November 5, 2026 - - Latest News -
Increased accountability can be the only response to expanding authority
November 5, 2026 - - Latest News -
Sydney summit program focused on the reshaping power of AI
November 4, 2026 - - Latest News -
Is the reluctance to revisit term limits because they are such an obvious change?
November 4, 2026 - - Latest News -
Does new report suggest that patient voice reforms are stalling?
November 4, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News